Fungal Infections

Invasive fungal diseases remain a major cause of morbidity and mortality in patients undergoing transplant, with shifting epidemiology, emerging resistance, and geographic variation underscoring the urgent need for improved surveillance, prevention strategies, and antifungal stewardship.

Candida auris is a highly drug-resistant, hospital-acquired fungal pathogen. With limited treatment options, here is an overview of some of the next-generation antifungals as well as combination therapeutics.

Most clinical isolates identified as triazole-resistant Aspergillus niger by traditional clinical laboratory methods were revealed by DNA sequencing to be A tubingensis.

A public health and farmworker coalition says agricultural spraying of medically important antibiotics and antifungals contributes to environmental resistance and warrants EPA cancellation.

The New Jersey company recently announced the partnership that includes federal funding to create new treatments from a novel class of fungerps.

CDC found 6.9% of those testing positive for Candida auris colonization on skin develop invasive infection, and calls for better surveillance and prevention.

Tennessee, New Jersey, North Carolina, and South Carolina were evaluated by Alexandra Kurutz, MPH, and Simone Godwin, DVM, MPH, MS, CIC, in a review of C auris containment efforts in dialysis facilities using standard IPC measures.

A retrospective study finds no significant difference in treatment failure between patients with obesity and those without.

At ASM Microbe 2025, a Puerto Rico study linked increased fungal spore concentrations to rises in viral respiratory infections, suggesting potential early warning utility.

At ASM Microbe 2025, a cross-sectional study highlighted Burkholderia cepacia dominance, widespread antibiotic resistance, and key risk factors, including invasive device use and patient demographics.

New modeling estimates up to 360,000 symptomatic cases annually, 10 to 18 times higher than reported, with CDC experts calling for expanded testing, reporting, and clinical awareness.

Q&A with Amy Cain discusses cannabidiol and cannabidivarin’s effects on fungal biofilms and drug-resistant strains.

This week, FDA approved Moderna’s improved COVID-19 vaccine mRNA, MAD-ID findings showed omadacycline’s 86% success rate in treating infections in immunocompromised patients, consistent safety in preventing recurrent CDI in patients with comorbidities, and more.

Mycovia Pharmaceuticals is evaluating oteseconazole against the standard of care for treating cryptococcal meningitis.

A published study reveals how an extra gene allows a specific mycetoma-causing fungus to neutralize itraconazole when treating the neglected tropical disease.

Innoviva launches ceftobiprole in the US, shifts in FDA COVID-19 vaccine policy, a surge in fungal infections, and more.

The state reported 3123 cases, a significant jump from 2024's 1011 cases in the same period, with experts citing environmental factors.

SOF/VEL cured 98.9% of 7,027 hepatitis C cases globally, and peptide-decorated liposomes improved antifungal delivery against Candida species, and more

Posaconazole-loaded liposomes decorated with penetratin show up to 1300 times increased efficacy against biofilm formation and reduce fungal burden by 60% in murine models.

As therapies that impact the immune system become more common, patients are living longer but with increased susceptibility to infections, including viral, bacterial, fungal, and emerging diseases.

A study of an H5N1 strain from a Michigan dairy worker showed airborne transmission in ferrets, bulevirtide achieved sustained virologic response in chronic hepatitis D patients, and more.

Study supports the global need for targeted education to correct misconceptions and improve treatment adherence.

The latest fungal-focused edition of the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases explores the global spread of antifungal resistance, rising cases of Aspergillus infections, and the detection of Histoplasma.

Scynexis developed its investigational fungal compound, SCY-247, which is in phase 1 clinical trials, and the company expects to share top-line data this year.

This week, the CDC ACIP's endorsement of meningococcal, RSV, and chikungunya vaccines, the need to expand automated CD4 testing for improved HIV/AIDS care, and more.